0:42Talk to us about what you found, Bill.
0:45Thanks for having me.
0:46And just as a reminder about what FAME3 was, when we think of multivessel disease and revascularization strategies, the kind of divide it into two groups, left main patients or patients with three vessel disease not involving the left main.
1:02And we have some fairly contemporary data in the left main space with Accel and Noble.
1:07But in the three-vessel disease not involving left main, sort of the granddaddy is the syntax trial.
1:14We don't have up-to-date data.
3:06And what did you see?